The key to fighting sepsis
Australian and US researchers have identified a gene that triggers the inflammatory condition that can lead to the full-body infection sepsis. The gene’s discovery could potentially lead to the development of new treatments for the deadly disease.
Sepsis is a severe whole-body infection that kills thousands of Australians each year. It occurs as a complication to an existing infection and, if not treated quickly, can lead to septic shock and multiple organ failure, with death rates as high as 50%.
Researchers were aware that sepsis occurs when molecules known as lipopolysaccharides (LPS) on the surface of some bacteria infiltrate cells, triggering an immune response that causes the cells to self-destruct. The team discovered that the protein Gasdermin-D played a critical role in this process.
Scientists at US biotech company Genentech showed that Gasdermin-D usually exists in cells in an inactive form. When the LPS molecules enter the cells they trigger an enzyme called caspase-11 — a kind of chemical hatchet — to lop the protective chemical cap off Gasdermin-D, which in turn leads the cells to self-destruct.
Researchers at the Australian Phenomics Facility, located in The John Curtin School of Medical Research at the Australian National University (ANU), proceeded to screen thousands of genes with a large-scale forward genetics discovery platform. In a little over a year, they had isolated the gene that produces Gasdermin-D.
“This finding is a key that could potentially unlock our ability to shut down [sepsis]… before it gets to a life-threatening stage,” said co-author Chris Goodnow from ANU.
“The identification of Gasdermin-D can give us a better understanding not only of lethal sepsis, but also of multiple other inflammatory diseases,” added co-author Dr Nobuhiko Kayagaki, a senior scientist at Genentech.
The study has been published in the journal Nature.
Could this psychedelic compound reduce post-concussion symptoms?
Few effective therapies exist for concussion. Now, an Australian clinical trial is exploring...
Turning point — optimal antibiotics for golden staph bloodstream infections
Involving more than 150 hospitals across more than 14 countries, a global clinical trial supports...
Alloy implants that naturally dissolve after healing
Australian researchers have been developing biodegradable magnesium-based alloys that more...
